Cost Insights: Breaking Down AbbVie Inc. and Evotec SE's Expenses

Comparative cost analysis of AbbVie Inc. and Evotec SE.

__timestampAbbVie Inc.Evotec SE
Wednesday, January 1, 2014442600000060118000
Thursday, January 1, 2015450000000089690000
Friday, January 1, 20165833000000105953000
Sunday, January 1, 20177040000000175062000
Monday, January 1, 20187718000000263389000
Tuesday, January 1, 20197439000000313546000
Wednesday, January 1, 202015387000000375181000
Friday, January 1, 202117446000000466491000
Saturday, January 1, 202217414000000577383000
Sunday, January 1, 202320415000000606375000
Monday, January 1, 202416904000000
Loading chart...

Unlocking the unknown

Cost Insights: A Comparative Analysis of AbbVie Inc. and Evotec SE's Expenses

In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue for two industry players: AbbVie Inc. and Evotec SE, from 2014 to 2023. Over this period, AbbVie Inc. has seen a staggering 361% increase in its cost of revenue, peaking at approximately $20 billion in 2023. This growth reflects its aggressive expansion and investment in research and development. In contrast, Evotec SE, a smaller entity, experienced a 910% rise, reaching around $606 million in 2023. While AbbVie's costs are significantly higher, Evotec's rapid growth rate highlights its dynamic approach in the biotech sector. This comparative insight underscores the diverse strategies and financial trajectories within the pharmaceutical industry, offering a window into the operational priorities of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025